Measures in rheumatoid arthritis: Are we measuring too many parameters

International Journal of Rheumatic Diseases

Volumn 15, Issue 3, 2012, Pages 239-248

  Chandrashekara, S ^a   Sachin, S ^a  

^a ChanRe Rheumatology and Immunology Center and Research   (India)

Author keywords

CRP; Disease activity measures; Joint counts; Rheumatoid arthritis; Tight control

Indexed keywords

C REACTIVE PROTEIN;

ACCURACY; CLINICAL ASSESSMENT TOOL; DISEASE ACTIVITY; GRIP STRENGTH; HUMAN; INFLAMMATION; JOINT BIOPSY; JOINT DESTRUCTION; JOINT SWELLING; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PAIN; PHYSICAL DISABILITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIOLOGY; RELIABILITY; REPRODUCIBILITY; REVIEW; RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS; VISUAL ANALOG SCALE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DIAGNOSTIC TECHNIQUES AND PROCEDURES; HUMANS; INFLAMMATION MEDIATORS; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; RHEUMATOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84862585244     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/j.1756-185X.2012.01754.x     Document Type: Review

References (73)

1. Smolen JS, Aletaha D, Koeller M et al. (2007) New therapies for treatment of rheumatoid arthritis. Lancet 370, 1861-74.
2. Symmons DP (2010) Rheumatoid arthritis: assessing disease activity and outcome. Clin Med 10, 248-51.
3. Sokka T (2010) How should rheumatoid arthritis disease activity be measured today and in the future in clinical care? Rheum Dis Clin North Am 36, 243-57.
4. Arnett FC, Edworthy SM, Bloch DA et al. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31, 315-24.
5. Aletaha D, Neogi T, Silman AJ et al. (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62, 2569-81.
6. Pinals RS, Masi AT, Larsen RA et al. (1981) Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 24, 1308-15.
7. Paulus HE, Egger MJ, Ward JR et al. (1990) Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group. Arthritis Rheum 33, 477-84.
8. Hochberg MC, Chang RW, Dwosh I et al. (1992) The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 35, 498-502.
9. Felson DT, Anderson JJ, Boers M et al. (1993) The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 36, 729-40.
10. van der Heijde DM, van't Hof M, van Riel PL et al. (1993) Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 20, 579-81.
11. Felson DT, Anderson JJ, Boers M et al. (1995) American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38, 727-35.
12. Prevoo ML, van't Hof MA, Kuper HH et al. (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38, 44-8.
13. van Gestel AM, Prevoo ML, van't Hof MA et al. (1996) Development and validation of the european league against rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 39, 34-40.
14. Felson D (2007) A proposed revision to the ACR20: the hybrid measure of American College of Rheumatology response. Arthritis Rheum 57, 193-202.
15. Felson DT, Smolen JS, Wells G et al. (2011) American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 63, 573-86.
16. Pincus T, Breedveld FC, Emery P (1999) Does partial control of inflammation prevent long-term joint damage? Clinical rationale for combination therapy with multiple disease-modifying antirheumatic drugs Clin Exp Rheumatol 17(Suppl.18), S2-7.
17. Capriotti T (2007) Rheumatoid arthritis. Understanding joint damage and inflammation. Adv Nurse Pract 15, 61-2, 64-6, 94.
18. Paulus HE, Scott DL, Edmonds JP (1992) Classification of antirheumatic drugs. A new proposal. Arthritis Rheum 35, 364-5.
19. Scott DL, Houssien DA (1996) Joint assessment in rheumatoid arthritis. Br J Rheumatol 35(Suppl.2), 14-8.
20. Ainola MM, Mandelin JA, Liljeström MP et al. (2005) Pannus invasion and cartilage degradation in rheumatoid arthritis: involvement of MMP-3 and interleukin-1beta. Clin Exp Rheumatol 23, 644-50.
21. Boesen M, Ostergaard M, Cimmino MA et al. (2009) MRI quantification of rheumatoid arthritis: current knowledge and future perspectives. Eur J Radiol 71, 189-96.
22. Bombardieri S, Ferraccioli G, Ferri C et al. (2009) Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNF alpha drugs. Reumatismo 61(Suppl.1), 1-23.
23. Karmakar S, Kay J, Gravallese EM (2010) Damage in rheumatoid arthritis: mechanistic insights and approaches to prevention. Rheum Dis Clin North Am 36, 385-404.
24. Suresh E (2010) Recent advances in rheumatoid arthritis. Postgrad Med J 86, 243-50.
25. Filer A, de Pablo P, Allen G et al. (2011) Utility of ultrasound joint counts in the prediction of rheumatoid arthritis in patients with very early synovitis. Ann Rheum Dis 70, 500-7.
26. Pincus T (2008) Limitations of a quantitative swollen and tender joint count to assess and monitor patients with rheumatoid arthritis. Bull NYU Hosp Jt Dis 66, 216-23.
27. Salaffi F, Filippucci E, Carotti M et al. (2008) Inter-observer agreement of standard joint counts in early rheumatoid arthritis: a comparison with grey scale ultrasonography - a preliminary study. Rheumatology (Oxford) 47, 54-8.
28. Scott DL, Choy EHS, Greeves A et al. (1996) Standardizing joint assessment in rheumatoid arthritis. Clin Rheumatol 15, 579-82.
29. Pincus T, Amara I, Segurado OG et al. (2008) Relative efficiencies of physician/assessor global estimates and patient questionnaire measures are similar to or greater than joint counts to distinguish adalimumab from control treatments in rheumatoid arthritis clinical trials. J Rheumatol 35, 201-5.
30. Sokka T, Toloza S, Cutolo M et al. (2009) Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST - RA study. Arthritis Res Ther 11, R7.
31. Ward MM (2004) Relative sensitivity to change of the erythrocyte sedimentation rate and serum C - reactive protein concentration in rheumatoid arthritis. J Rheumatol 31, 884-95.
32. Fransen J, Stucki G, van Riel Piet LCM (2003) Rheumatoid arthritis measures: Disease Activity Score (DAS), Disease Activity Score-28 (DAS28), Rapid Assessment of Disease Activity in Rheumatology (RADAR), and Rheumatoid Arthritis Disease Activity Index (RADAI). Arthritis Care Res 49, S214-24.
33. Anderson JJ, Chernoff MC (1993) Sensitivity to change of rheumatoid arthritis clinical trial outcome measures. J Rheumatol 20, 535-7.
34. Moya Alvarado P, Laiz A (2011) Is DAS a profitable score to be used for rheumatoid arthritis patient follow up? Reumatol Clin 7, 336-8.
35. Verhoeven AC, Boers M, van Der Linden S (2000) Responsiveness of the core set, response criteria, and utilities in early rheumatoid arthritis. Ann Rheum Dis 59, 966-74.
36. Llorca J, Gonzalez Quiros M, Sampedro I et al. (2002) Reproducibility of C-reactive protein analyses. Rev Esp Cardiol 55, 1101-4.
37. Bull BS, Westengard JC, Farr M et al. (1989) Efficacy of tests used to monitor rheumatoid arthritis. Lancet 2, 965-7.
38. Giles JT, Bartlett SJ, Andersen R et al. (2008) Association of body fat with C -reactive protein in rheumatoid arthritis. Arthritis Rheum 58, 2632-41.
39. Prevoo ML, van Riel PL, van't Hof MA et al. (1993) Validity and reliability of joint indices. A longitudinal study in patients with recent onset rheumatoid arthritis. Br J Rheumatol 32, 589-94.
40. van der Heijde DM, van't Hof MA, van Riel PL et al. (1992) Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis 51, 177-81.
41. Aletaha D, Smolen J (2005) The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 23(Suppl.39), S100-8.
42. Goldsmith CH, Smythe HA, Helewa A (1993) Interpretation and power of a pooled index. J Rheumatol 20, 575-8.
43. Crowson CS, Rahman MU, Matteson EL (2009) Which measure of inflammation to use? A comparison of erythrocyte sedimentation rate and C - reactive protein measurements from randomized clinical trials of golimumab in rheumatoid arthritis J Rheumatol 36, 1606-10.
44. Makinen H, Hannonen P (2009) How to assess patients with rheumatoid arthritis and concomitant fibromyalgia. J Rheumatol 36, 9-11.
45. Grigor C, Capell H, Stirling A et al. (2004) Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364, 263-9.
46. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF et al. (2005) Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the Best study): a randomized, controlled trial. Arthritis Rheum 52, 3381-90.
47. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF et al. (2008) Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the Best study): a randomized, controlled trial. Arthritis Rheum 58(Suppl.), S126-35.
48. Rantalaiho V, Korpela M, Hannonen P et al. (2009) The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven year results of the Finnish rheumatoid arthritis combination therapy trial. Arthritis Rheum 60, 1222-31.
49. Rantalaiho V, Korpela M, Laasonen L et al. (2010) Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial. Arthritis Res Ther 12, R122.
50. Rau R, Wassenberg S (2003) Imaging techniques in rheumatology: scoring methods in rheumatoid arthritis. Z Rheumatol 62, 555-65.
51. Fukae J, Koike T (2009) Imaging methods in rheumatoid arthritis. Clin Calcium 19, 311-5.
52. Scire CA, Montecucco C, Codullo V et al. (2009) Ultrasonographic evaluation of joint involvement in early rheumatoid arthritis in clinical remission: power Doppler signal predicts short-term relapse. Rheumatology (Oxford) 48, 1092-7.
53. Bingham SJ, Buch MH, Tennant A et al. (2004) The impact of escalating conventional therapy in rheumatoid arthritis patients referred for anti-tumour necrosis factor-alpha therapy. Rheumatology (Oxford) 43, 364-8.
54. Deighton C, Hyrich K, Ding T et al. (2010) BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. Rheumatology (Oxford) 49, 1197-9.
55. Molenaar ET, Voskuyl AE, Dinant HJ et al. (2004) Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum 50, 36-42.
56. Brown AK, Conaghan PG, Karim Z et al. (2008) An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum 58, 2958-67.
57. Brown AK, Quinn MA, Karim Z et al. (2006) Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug - induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum 54, 3761-73.
58. Graf J, Scherzer R, Grunfeld C et al. (2009) Levels of C - reactive protein associated with high and very high cardiovascular risk are prevalent in patients with rheumatoid arthritis. PLoS ONE 4, e6242.
59. Schwenger V, Sis J, Breitbart A et al. (1998) CRP levels in autoimmune disease can be specified by measurement of procalcitonin. Infection 26, 274-6.
60. Kalabalikis P, Papazoglou K, Gouriotis D et al. (1999) Correlation between serum IL-6 and CRP levels and severity of head injury in children. Intensive Care Med 25, 288-92.
61. Fisk NM, Fysh JW (1988) C-reactive protein (CRP) as a marker for infection. Acta Obstet Gynecol Scand 67, 189.
62. Annuk M, Soveri I, Zilmer M et al. (2005) Endothelial function, CRP and oxidative stress in chronic kidney disease. J Nephrol 18, 721-6.
63. Wener MH, Daum PR, McQuillan GM et al. (2000) The influence of age, sex, and race on the upper reference limit of serum C-reactive protein concentration. J Rheumatol 27, 2351-9.
64. Brennan FM, Browne KA, Green PA et al. (1997) Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy. Br J Rheumatol 36, 643-50.
65. Ichikawa Y, Yamada C, Horiki T et al. (1998) Serum matrix metalloproteinase-3 and fibrin degradation product levels correlate with clinical disease activity in rheumatoid arthritis. Clin Exp Rheumatol 16, 533-40.
66. Keyszer G, Lambiri I, Nagel R et al. (1999) Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers. J Rheumatol 26, 251-8.
67. Ribbens C, Andre B, Jaspar JM et al. (2000) Matrix metalloproteinase-3 serum levels are correlated with disease activity and predict clinical response in rheumatoid arthritis. J Rheumatol 27, 888-93.
68. Koksal N, Harmanci R, Cetinkaya M et al. (2007) Role of procalcitonin and CRP in diagnosis and follow-up of neonatal sepsis. Turk J Pediatr 49, 21-9.
69. Massaro KS, Costa SF, Leone C et al. (2007) Procalcitonin (PCT) and C-reactive protein (CRP) as severe systemic infection markers in febrile neutropenic adults. BMC Infect Dis 7, 137.
70. Nishino J, Tanaka S, Kadono Y et al. (2010) The usefulness of neutrophil CD64 expression in the diagnosis of local infection in patients with rheumatoid arthritis in daily practice. J Orthop Sci 15, 547-52.
71. Sokka T, Pincus T (2009) Erythrocyte sedimentation rate, C-reactive protein, or rheumatoid factor are normal at presentation in 35% - 45% of patients with rheumatoid arthritis seen between 1980 and 2004: analyses from Finland and the United States. J Rheumatol 36, 1387-90.
72. de Bandt M, Fautrel B, Maillefert JF et al. (2009) Determining a low disease activity threshold for decision to maintain disease-modifying antirheumatic drug treatment unchanged in rheumatoid arthritis patients. Arthritis Res Ther 11, R157.
73. Saleem B, Nizam S, Emery P (2006) Can remission be maintained with or without further drug therapy in rheumatoid arthritis? Clin Exp Rheumatol 24(Suppl.43), S33-6.